Ptc Therapeutics (PTCT) EBIAT (2016 - 2025)
Ptc Therapeutics (PTCT) has 14 years of EBIAT data on record, last reported at $414.1 million in Q4 2025.
- For Q4 2025, EBIAT rose 728.53% year-over-year to $414.1 million; the TTM value through Dec 2025 reached $1.2 billion, up 426.61%, while the annual FY2025 figure was $1.2 billion, 442.41% up from the prior year.
- EBIAT reached $414.1 million in Q4 2025 per PTCT's latest filing, up from -$23.1 million in the prior quarter.
- Across five years, EBIAT topped out at $866.6 million in Q1 2025 and bottomed at -$198.9 million in Q2 2023.
- Average EBIAT over 5 years is -$44.3 million, with a median of -$122.5 million recorded in 2021.
- Peak YoY movement for EBIAT: crashed 123.47% in 2021, then soared 1046.28% in 2025.
- A 5-year view of EBIAT shows it stood at -$143.3 million in 2021, then decreased by 19.28% to -$170.9 million in 2022, then rose by 8.83% to -$155.8 million in 2023, then soared by 57.71% to -$65.9 million in 2024, then surged by 728.53% to $414.1 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were $414.1 million in Q4 2025, -$23.1 million in Q3 2025, and -$71.1 million in Q2 2025.